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Objectives: The aim of this study was to investigate the influence of body mass index (BMI) on clinical and meta-
bolic characteristics in patients with polycystic ovary syndrome (PCOS).
Methods: A total of 67 patients with PCOS were included in this study. Study subjects were divided into two groups 
according to BMI: women with BMI ≥23 kg/m2 (overweight/obese group, n=24) vs. women with BMI <23 kg/m2 
(normal-weight group, n=43). We compared clinical and metabolic characteristics including waist-to-hip ratio, serum 
lipid profiles, homeostatic model assessment of insulin resistance (HOMA-IR), fasting serum glucose/insulin ratio, 
postprandial 2 hours (PP2) serum insulin levels, total testosterone, sex hormone-binding globulin (SHBG), high-sensi-
tivity C-reactive protein (hs-CRP) and homocysteine levels between the two groups, which were statistically analyzed 
using Mann-Whitney U test or Fisher’s exact test, where appropriate.
Results: The overweight/obese group has a lower serum SHBG level (37.23±26.74 vs. 66.42±40.16 nmol/l, P= 
0.004) and a higher free androgen index (5.83±3.85 vs. 3.57±2.30, P=0.002) than the normal-weight group. Fasting 
insulin (17.13±8.8 vs. 7.15±4.41 μIU/ml, P<0.001), PP2 insulin (76.81±43.66 vs. 47.98±49.77 uIU/ml, P=0.022) 
and the HOMA-IR (3.65±1.74 vs. 1.48±1.02, P<0.001) are significantly higher and fasting glucose/insulin ratio
(6.59±4.84 vs. 15.18±7.48, P<0.001) are significantly lower in the overweight/obese group compared to those of 
the normal weight group. Serum triglyceride (125.00±105.34 vs. 77.56±41.69 mg/dl, P=0.036) and hs-CRP levels
(3.53±4.23 vs. 0.85±0.70 mg/l, P=0.008) are significantly higher in the overweight/obese group. 
Conclusion: The overweight and obese women with PCOS are more closely related to hyperandrogenism, insulin re-
sistance and chronic inflammation. These findings may indicate that they have an increased risk of metabolic and 
cardiovascular diseases.
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  ٖۗনٍীஹบ ֞ฅୀଭඌ ఼ֹா߆஺৤(body 
mass index, BMI)ۀԨيޭࠬۗۗઑ෇࡝ࢠ֝ଲ
35 kg/m2 ଲঃଞߦԧୋڔ .ۗ10～12 ছ֜઩ण෇઱
ੰਏੰ஺લଭٖۗনٍীஹบ ֞ฅୀ઩ছण࠮
କࣦࠔଠٗଠՓଞߦੵߙ୲଼ଞ࡝ౖ ֽ࣪ճܤ
֝ ٖٛۗনٍীஹบ֞ฅୀ઩ছण࠮ଠ 28.4%, 




















ীஹบ֞ଭ஼ۚଠ 2003 Rotterdam ஼ۚ׆ஜଡ
ୡ૳෇઱ۗଣ3ԧ஺׆ஜண2ԧ஺ଲঃଡ࠮୻









ۚ෇઼ճ ֻ ٛ૳ଠ ۗଣր Զ :ۗ Ferriman- 
Gallwey scale 8୥ଲঃଲՋي,16 total testosterone 







ছ ୪૤෇઼ .ۗ ށ෉, ෯ண 17-alpha-hydroxypro-
gesterone (17-OHP) ৤౿ԧ3 ng/ml ଲঃଡ׆ஜଞ
ߦ෇઱णୢ෴෴টవনऀ਑րஹਐ(non-classi-
cal congenital adrenal hyperplasia)ଲଭਕܣۀฅ
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ୀۀ઴֜۩ঃ઩ছ୪૤෇઼ .ۗ 
  ఼ா߆஺৤ 23 kg/m2ଡ׆ஜଞߦր఼ண/ण࠮
֞ଠ24ࡣଲતճ, 23 kg/m2 ࢠ࠮଴୨ঃ఼ண֞ଠ
43ࡣଲત .ۗ
2. 연구방법






ssayࠜ ଲ૳෇઱ จ఼෴ন෹࠙ࡩ(luteinizing hor-
mone, LH; ADVIA Centaur LH ReadyPack primary 
reagent pack), ٍඑୀּ෹࠙ࡩ(follicle stimulating 
hormone, FSH; ADVIA Centaur FSH ReadyPack 
primary reagent pack), ઩ਆൈޭ݌ો(estradiol, E2; 
ADIVA Centaur Estradiol-6 ReadyPack), ౑ഓਆഠ
ਆഓߨ(total testosterone; Cobas 6000, Roche Diag-
nostics GmbH, Mannheim, Germany), ন෹࠙ࡩէ
෍ۚࢽ(sex hormone-binding globulin (SHBG); 
Cobas 600, Roche Diagnostics GmbH, Mannheim, 
Germany), dehydroepiandrosterone sulfate (DHEAS), 
17-OHPࠜ౸୨෇ճ, ౑෹ࡦਏਆഓ଴(homocyste-
ine), high sensitivity C-reactive protein (hs-CRP)ࠜ
ंজ෇઼ .ۗ Free androgen index (FAI)ۀ total 
testosterone/SHBG x 3.47 (%)ߦծॺ෇઼ .ۗ 75 g 
լ֜ۥऀ෇Ցॷࠜਏෘ෇઱վ࣫ਏ෯ۥր଴
ਂ ,ࠦ ۥऀ෇2ਏԩบ෯ۥր଴ਂࠦଡ౸୨෇
઼ճ, homeostatic model assessment of insulin 
resistance (HOMA-IR, glucose (mg/dL) x insulin
(µU/mL)/405)ࠜծॺ෇઼ .ۗ ෯ண౑಻ߑਆഓߩ, 
ணন஺ࢺ(triglycerides), ୠࢤܑ஺ۚࢽ(low-density 
lipoprotein-cholesterol, LDL-C), ճࢤܑ஺ۚࢽ(high- 
density lipoprotein-cholesterol, HDL-C)ଡ౸୨෇઼
.ۗ ށ෉, The National Cholesterol Education Pro-




80 cm ଲঃ; վ࣫෯ۥ100 mg/dl ଲঃ; ணন஺ࢺ
150 mg/dl ଲঃ; ճࢤܑ஺ۚࢽ50 mg/dl ࢠ࠮; ෯
੺130/85 mmHg ଲঃ.18
3. 통계분석
  ઴֜էր઩ ۩෉ ധծୡ ंজଠ Statistical 
Package for the Social Sciences for Windows ver-
sion 12.0 (SPSS Inc., Chicago, IL, USA)ଡଲ૳෇
઱ਓਏ෇઼ .ۗ ઑ֞ଭԨ࣡৤ࠜण֗෇׆଍෇




결    과
  ր఼ண/ण࠮֞ଠ୨ঃ఼ண֞઩ण෇઱ෛࠤܭ
ߑ(95.47±7.10 vs. 73.36±7.35 cm, P<0.001), થ۾
ଲܭߑ(108.73±5.97 vs. 93.17±4.16 cm, P<0.001), 
ෛ -ࠤથ۾ଲܭߑण(0.88±0.04 vs. 0.79±0.06, P< 
0.001)ԧକଭ෇՚ڔ੼ۗ(Table 1). ෯ணഓਆഠ
ਆഓߨړܑۀକଭ෉ఙଲԧઢતଞيր఼ண/ण
࠮֞઩ছ ෯ண SHBG ړܑԧ କଭ෇՚ ٗ੼ճ
(37.23±26.74 vs. 66.42±40.1 6 nmol/L, P=0.002), 
FAI (5.83±3.85 vs. 3.57±2.30%, P=0.004)ۀକଭ
෇՚ڔ੼ .ۗ ઑ֞ԩଁլଲঃଭઑঃ, ෯ண




8.77 vs. 7.15±4.41 μIU/mL, P<0.001; 76.81±43.66 
vs. 47.98±49.77 μIU/ml, P=0.022), HOMA- 
IR (3.65±1.74 vs. 1.48±1.02, P<0.001)ଠକଭ෇
՚ ڔ੼ճ վ࣫ ਏ /ۥ଴ਂࠦ ण(6.59±4.84 vs. 
15.18±7.48, P<0.001)ۀ କଭ෇՚ ٗ੼ۗ(Table 
2). ր఼ண/ण࠮֞઩ছ෯ணணন஺ࢺړܑ(125.00 




Table 1. Clinical characteristics between overweight/obese and normal-weight women with polycystic ovary 
syndrome
Overweight/obese (n=24) Normal-weight (n=43) P value
Age (years)  25.54±5.94  24.63±5.02  0.506
Weight (kg)  75.04±9.34  52.29±6.61 <0.001*
Height (m)   1.55±31.73   1.57±25.61  0.856
BMI (kg/m2)  28.94±3.56  20.07±1.91 <0.001*
Waist (cm)  95.47±7.10  73.36±7.35 <0.001*
Hip (cm) 108.73±5.97  93.17±4.16 <0.001*
Waist-to-hip ratio   0.88±0.04   0.79±0.06 <0.001*
Right ovarian volume (cm3)   4.98±5.26   6.31±6.55  0.393
Left ovarian volume (cm3)   4.69±4.47   6.94±6.74  0.140
LH (mIU/mL)   7.03±4.65   8.10±5.10  0.388
FSH (mIU/mL)   6.14±4.68   4.84±1.57  0.105
LH/FSH ratio   1.33±0.99   1.61±0.87  0.214
Estradiol (pg/mL)  28.13±24.77  41.78±55.69  0.293
Total testosterone (ng/dL)  46.06±18.29  57.03±29.80  0.098
SHBG (nmol/L)  37.23±26.74  66.42±40.16  0.002*
FAI (%)   5.83±3.85   3.57±2.30  0.004*
DHEAS (µg/mL) 161.12±112.85 168.32±88.31  0.771
17-OHP (ng/mL)   0.99±0.78   1.12±0.72  0.501






    61.9
     5.9
 0.242
BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; SHBG, sex hormone-binding 
globulin; FAI, free androgen index; DHEAS, dehydroepiandrosterone sulfate; 17-OHP, 17 hydroxyprogesterone Values 
are represented as mean±standard deviation. *significantly different between groups (P<0.05).
Table 2. Metabolic characteristics between overweight/obese and normal-weight women with polycystic ovary 
syndrome
Overweight/obese (n=24) Normal-weight (n=43) P value
Fasting glucose (mg/dL)  86.13±20.51  85.84±6.41  0.937
Postprandial 2hr glucose (mg/dL) 110.25±42.89  95.92±22.22  0.141
Fasting insulin (µIU/mL)  17.13±8.77   7.15±4.41 <0.001*
Postprandial 2hr insulin (µIU/mL)  76.81±43.66  47.98±49.77  0.022*
Fasting glucose/insulin ratio   6.59±4.84  15.18±7.48 <0.001*
HOMA-IR   3.65±1.74   1.48±1.02 <0.001*
Total cholesterol (mg/dL) 175.00±51.49 166.59±43.96  0.478
Triglyceride (mg/dL) 125.00±105.34  77.56±41.69  0.036*
LDL-C (mg/dL) 106.73±37.44  92.35±30.17  0.090
HDL-C (mg/dL)  53.12±24.84  57.61±17.97  0.394
Homocysteine (µmol/L)  11.40±2.43  11.08±2.53  0.620
hs-CRP (mg/L)   3.53±4.23   0.85±0.70  0.008*
Metabolic syndrome (%)     20.83      2.33  0.003*
HOMA-IR, HOMA-IR index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; 
hs-CRP, high-sensitivity C-reactive protein Values are represented as mean±standard deviation. *significantly different 
between groups (P<0.05).
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Fig. 1. The correlation of serum high sensitivity C-reactive protein with body mass index, free androgen index 
and homeostasis model assessment-insulin resistance.
ࢤܑ஺ۚࢽ ړܑۀକଭ෉ఙଲԧઢતۗ(Table 
2). hs-CRPۀր఼ண/ण࠮֞઩ছକଭ෇՚ڔ੼ଞ
ي(3.53±4.23 vs. 0.85±0.70 mg/l, P=0.008), ෹ࡦ
ਏਆഓ଴ଠઑ֞ԩఙଲԧઢતଞ࡝, ۩ॷஹบ֞
ଠր఼ண/ण࠮֞઩ছକଭ෇՚ڔଠणଘଡ઼࣪
(ۗ20.83 vs. 2.33%, P=0.003) (Table 2). ࡦ݃ٖۗ
নٍীஹบ֞ฅୀࠜ۩ঃଞߦhs-CRP૕କଭ෉
ঃւ ւծࠜ Դۀ ࣡৤ۀ ఼ா߆஺৤(r=0.461, 
P=0.000)ߦ, يଲ(r=0.181, P=0.185), ෛ -ࠤથ۾ଲ
ܭߑण(r=0.295, P=0.081), Ferriman-Gallwey scale 
(r=-0.084, P=0.598), ౑ഓਆഠਆഓߨ(r=-0.135, 
P=0.329), HOMA-IR (r=0.218, P=0.081), FAI (r= 
0.046, P=0.736), ౑಻ߑਆഓߩ(r=0.230, P=0.206), 
ୠࢤܑ஺ۚࢽ(r=0.175, P=0.207), ճࢤܑ஺ۚࢽ(r= 
-0.079, P=0.668), ணন஺ࢺ(r=0.209, P=0.252)ր
ۀକଭ෉ւߛনଲઢતۗ(Fig. 1). 















݅ண఼ா߆஺৤25 kg/m2 ଲঃ଴ฅୀۀ32.8%, 










ߦ 5,750ࡣଭ ෉֝଴ଡ ۩ঃଞߦ ෉ 1995ڂ







ॷୡ൉௃ଭఙଲԧण਍෇઼ .ۗ ֻ߇ي, ࣭઴֜






















෇࡝ށ෉tumor necrosis factor-α (TNF-α)૕leptin
ଭ଴ਂࠦ৤૳఼઩۩෉ୁ૳ଞߦ଴ਂࠦୠා
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ࠜைூ׆෉ٖۗনٍীஹบ֞ฅୀ૕൉ࢳনճ
ੲ݁ߦ՛ஹฅୀࠜण֗෇઼ۀ܁, ٖۗনٍীஹ
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연구대상 및 방법: ୢ఼ٖۗনٍীஹบ֞ฅୀ67ࡣண఼ா߆஺৤23 kg/m2 ଲঃ଴ฅୀ
(ր఼ண/ण࠮ ,֞ n=24)૕఼ா߆஺৤23 kg/m2 ࢠ࠮଴ฅୀ(୨ঃ఼ண ,֞ n=43)઩ছيଲ, ෛ
ࠤܭߑ, થ۾ଲܭߑ, ఼ா߆஺৤, ଁլச׆, ొଣ൞ࠜധ෉ٖۗনٍী઱ऀࠜण֗෇
ճ, Ferriman-Gallwey scaleଡ౸୨෇઼ .ۗ ෹࠙ࡩՑॷࢫ౑ഓਆഠਆഓߨ, ন෹࠙ࡩէ෍
ۚࢽଡ౸୨෇઱free androgen index (FAI)ࠜծॺ෇઼ .ۗ 75 g ۥऀ෇Ցॷࠜധැվ࣫
ਏ૕2ਏԩบ෯ۥր଴ਂࠦଡ౸୨෇ճhomeostatic model assessment of insulin resistance 
(HOMA-IR)ଡ ծॺ෇઼ଞ࡝, ஺ா Ցॷ ࢫ ෹ࡦਏਆഓ଴ր high-sensitivity C-reactive 
protein (hs-CRP)ࠜՑॷ෇઼ .ۗ 
결과: ր఼ண/ण࠮෉ٖۗনٍীஹบ֞ฅୀۀ୨ঃ఼ணฅୀ࣪ۗন෹࠙ࡩէ෍ۚࢽ৤౿
ԧ۳ٗճ(37.23±26.74 vs. 66.42±40.16 nmol/l, P=0.004), FAI (5.83±3.85 vs. 3.57±2.30, 
P=0.002)ۀ۳ڔ੼ .ۗ վ࣫ր2ਏԩۥऀ෇บ଴ਂࠦ৤౿, HOMA-IRଲକଭ෇՚ڔ੼ଞ
࡝(17.13±8.77 vs. 7.15±4.41 μIU/mL, P<0.001; 76.81±43.66 vs. 47.98±49.77 μIU/mL, 
P=0.022; 3.65±1.74 vs. 1.48±1.02, P<0.001), վ࣫ /ۥ଴ਂࠦण(6.59±4.84 vs. 15.18±7.48, 
P<0.001)ۀ ۳ ٗ੼ .ۗ ށ ր఼ண/ण࠮֞઩ছ ணন஺ࢺ(125.00±105.34 vs. 77.56±41.69 
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